---
title: "8+bulk结合单细胞公共数据库挖掘纯生信"
date: 2023-05-24T23:54:18Z
draft: ["false"]
tags: [
  "fetched",
  "生信人"
]
categories: ["Acdemic"]
---
8+bulk结合单细胞公共数据库挖掘纯生信 by 生信人
------
<div><section><section powered-by="xiumi.us"><p>今天小编给大家介绍的是今年5月发表在<strong><span>Journal of Translational Medicine(IF:8.440)</span></strong>上的一篇纯生信公共数据库挖掘的文章，本文综合了<span>bulk RNA-seq、scRNA-seq和空间转录组</span>数据揭示了在膀胱癌(BCs)中浆细胞(PCs)如何与肿瘤细胞交流，以及BCs患者对免疫检查点抑制剂(ICIs)的反应和临床结果的影响。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="0.3972222222222222" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92Cdenemvh1BI6TViaVJQWNNJILyXcLCKc4NmicSLB3NGicMn7n0zbX4DHEA/640?wx_fmt=png" data-w="1080" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92Cdenemvh1BI6TViaVJQWNNJILyXcLCKc4NmicSLB3NGicMn7n0zbX4DHEA/640?wx_fmt=png"></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section><svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 288.279 254.107" width="100%"><g><g><path d="M288.279,254.107,68.215,127.054,288.279,0ZM80.3,127.054,282.236,243.643V10.465Z" fill="rgb(62,62,62)"></path><polygon points="0 124.499 211.001 246.32 211.001 2.677 0 124.499" fill="rgb(49,102,168)"></polygon></g></g></svg></section></section></section></section><section><section><section powered-by="xiumi.us"><section><p><strong>背景</strong></p></section></section></section></section><section><svg viewbox="0 0 1 1"></svg></section></section><section powered-by="xiumi.us"><p>膀胱癌(BCs)具有固有的侵袭性，易复发的特性，患者通常需要多模式、有创性的治疗，但其无复发生存率较低。免疫检查点抑制剂(ICI)相比其他治疗方法具有更好的安全性和更持久的反应，对进一步改善患者的临床管理和预后具有重要意义。肿瘤相关的三级淋巴结构(TLSs)最近被发现，并与BC患者更好的生存和免疫反应相关，TLSs中不仅含有大量的T细胞，还含有大量的ICI反应性B细胞，浆细胞(PCs)是TLSs中关键的B细胞群，肿瘤相关的巨噬细胞、成纤维细胞和中性粒细胞已被报道与B细胞相互作用并介导其向PC的分化。然而，目前尚不清楚PC是否直接与肿瘤细胞相互作用，以及肿瘤细胞-PC通讯在BC中起什么作用。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section><svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 288.279 254.107" width="100%"><g><g><path d="M288.279,254.107,68.215,127.054,288.279,0ZM80.3,127.054,282.236,243.643V10.465Z" fill="rgb(62,62,62)"></path><polygon points="0 124.499 211.001 246.32 211.001 2.677 0 124.499" fill="rgb(49,102,168)"></polygon></g></g></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><p><strong>实验设计</strong></p></section></section></section><section><svg viewbox="0 0 1 1"></svg></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><br></section></section><section powered-by="xiumi.us"><section><img data-ratio="0.5611111111111111" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CMD7HQ4QDuZDf4wJRqxb4r4jTegvyf8pF2iccseIHTzEgj0KmfcKYE5w/640?wx_fmt=png" data-w="1080" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CMD7HQ4QDuZDf4wJRqxb4r4jTegvyf8pF2iccseIHTzEgj0KmfcKYE5w/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图1 流程图</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section><svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 288.279 254.107" width="100%"><g><g><path d="M288.279,254.107,68.215,127.054,288.279,0ZM80.3,127.054,282.236,243.643V10.465Z" fill="rgb(62,62,62)"></path><polygon points="0 124.499 211.001 246.32 211.001 2.677 0 124.499" fill="rgb(49,102,168)"></polygon></g></g></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><p><strong>结果</strong></p></section></section></section><section><svg viewbox="0 0 1 1"></svg></section></section><section powered-by="xiumi.us"><p><strong>1. PCs与患者生存和对免疫治疗的反应有关</strong></p></section><section powered-by="xiumi.us"><p>本章节<span>作者基于TCGA-BLCA bulk RNA-seq数据的细胞浸润推断分析</span>。在单变量Cox回归模型中，11种免疫细胞类型与总生存期(OS)显著相关，在所有B细胞类型中，只有class-switched memory B细胞和PCs与更好的OS显著相关(图2A和B)。在抗PD-L1处理的IMvigor210队列中的B细胞中，只有PCs与较好的OS相关(图2C和D)。此外，免疫治疗应答患者的PC丰度相对较高(图2E)。这些基于大量测序数据的细胞推断结果表明，BC患者的高PC浸润预示着更好的OS和对免疫治疗的反应。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.5075376884422111" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CT1lkpQcy3whOHeYjPO4ymj1aQ975VFjvibEIEzd7icwNY29CzFHiacsYQ/640?wx_fmt=png" data-w="796" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CT1lkpQcy3whOHeYjPO4ymj1aQ975VFjvibEIEzd7icwNY29CzFHiacsYQ/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图2 从bulk RNA-seq数据推断的浆细胞浸润水平与生存和免疫治疗反应相关</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>2. IgG1和IgA1是BC中PCs的两个主要亚型</strong></p></section><section powered-by="xiumi.us"><p>本章节<span>作者纳入了一个scRNA-seq数据集来探索单细胞水平上PC的异质性</span>。经过质控和细胞筛选，将其注释成三个大细胞亚群：上皮细胞(KRT18、EPCAM)，基质细胞(VWF、COL1A1)，免疫细胞(PTPRC、CD19、MS4A2)(图3A、B)。其中，依据PC标记物Cluster 11被鉴定为PCs(图3C、E)。与低级别患者相比，高级别患者的PCs减少(图3D上)。接下来，将未表达naive B细胞标记物的PCs进一步细分为7个簇(图3D下)，表明这些细胞都是成熟的PCs(图3E)。由于增殖相关基因MKI67的高表达，集群4被鉴定为质母细胞，而其他细胞主要表达IGHG1和IGHA1(图3F)。通过PCA进行基因降维后，我们发现几乎所有的PC都是高表达IGHG1和IGHA1的细胞，并且存在多个IgG亚型的细胞重叠。散点图也显示了两种细胞类型之间的显著差异(图3G)，表明IgG1和IgA1 PC是BC中主要的PC类型。为了进一步探究其功能特征，作者将IGHG1高表达、IGHA1低表达的细胞定义为IgG1 PCs，将IGHG1低表达、IGHA1高表达的细胞定义为IgA1 PCs。其中IgA1 PCs主要参与细胞周期相关的通路调控，而IgG1 PCs则显著参与免疫应答(图3G)。通过伪时间轨迹分析发现IgA1 PCs位于轨迹起点，IgG1 PCs主要位于轨迹末端(图3H)。同时，作者还发现IGHA1表达在轨迹结束时下降，而IGHG1表达增加(图3I)，这表明IgA1和IgG1 PCs之间可能存在类切换关系。进行细胞比例分析，作者发现在高级别疾病患者中IgA1 PCs增加，IgG1 PCs减少(图3J)。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="0.7851851851851852" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CSgxy3oyfOzQInOMibVBRBVFOO1rX4plSoeElcjvYsRIseOtXVbXFiaFw/640?wx_fmt=png" data-w="1080" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CSgxy3oyfOzQInOMibVBRBVFOO1rX4plSoeElcjvYsRIseOtXVbXFiaFw/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图3 单细胞分析鉴定浆细胞亚群</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>3. 六种肿瘤细胞状态的鉴定</strong></p></section><section powered-by="xiumi.us"><p>本章节<span>作者使用非负矩阵分解法(NMF)将肿瘤细胞鉴定为六种状态</span>。根据对单细胞的拷贝数推断分析，肿瘤细胞来自具有显著拷贝数变异(CNV)的上皮细胞(图4A)，来自高级别患者的细胞具有更高的CNV评分(图4B)。作者在BC中鉴定了六种肿瘤细胞状态(周期、基础、缺氧、部分上皮-间质转化[pEMT]、干扰素和应激)用于评估肿瘤细胞的内在功能特征(图4C和D)，发现不同状态的肿瘤细胞参与不同的调节功能(图4D)。尽管干扰素样肿瘤细胞的细胞比例最低，但它们的CNV评分最高(图4E)。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.3878718535469108" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CS12icpUc0RwY4IGetEtHfw2mGn3Cia3icqgoM6CiaQvLgd78eExHWStNeg/640?wx_fmt=png" data-w="874" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CS12icpUc0RwY4IGetEtHfw2mGn3Cia3icqgoM6CiaQvLgd78eExHWStNeg/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图4 用NMF鉴定六种细胞状态</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>4. 肿瘤细胞与PC间的串扰景观</strong></p></section><section powered-by="xiumi.us"><p>本章节<span>作者研究了所有细胞主要是肿瘤细胞与PC之间的通讯</span>。在配受体(L/R对)分析中，MIF/ (CD74+CD44或+CXCR4)和APP/CD74的L/R对是肿瘤细胞到PC信号转导中最突出的相互作用(图5A)。此外，在基于抗PD-L1治疗队列的L/R对与患者OS的相关性分析中，一些L/R对介导缺氧样和应激样肿瘤细胞向IgG1 PC(如ANGPTL4/SDC1和LAMB3/ CD44)的信号转导，显示出与患者OS恶化的显著相关性，表明这些L/R对可能在接受ICB治疗的患者中发挥特定作用。另一方面，一些趋化因子信号相关分子(如CXCL10和CXCL11)与患者更好的OS相关(图5A)，这些趋化因子由pEMT样肿瘤细胞分泌，可能通过ACKR1促进IgG1 PC的募集。</p><p><br></p><p>作者进一步研究了58对参与肿瘤细胞与PC之间重要通讯的L/R对的表达水平。在TCGA-BLCA队列中，33个分子在肿瘤和正常样本中差异表达，其中64%的分子在肿瘤样本中上调(图5B和C)。在抗PD-L1治疗IMvigor210队列中，16个分子在治疗应答和无应答患者中差异表达，但在应答患者中只有40%的分子上调(图5B和C)。由此作者推测肿瘤细胞和PC之间的全局串扰可能促进癌症的发展，并与对ICB治疗的不良反应有关。</p><p><br></p><p>为了进一步选择肿瘤细胞和PC之间可靠的L/R对，作者使用空间转录组分析评估了它们在组织切片中的表达水平。基于L/R对的表达和生物学定位分析，作者鉴定出肿瘤细胞与PCs之间具有高可靠性的两个L/R对(LAMB3/CD44和ANGPTL4/SDC1)。然而，作者发现ANGPTL4低表达，这表明其可能仅由某些特定的肿瘤细胞分泌。作者检测了ANGPTL4在不同细胞类型中的表达，发现它在上皮(肿瘤)细胞中显著表达，在一些基质细胞中表达程度较低(图5E)。在样本来源分析中，在样本B5和B7中观察到ANGPTL4明显的样本偏倚，这可能与它们明显的缺氧水平有关(图5F和G)。缺氧条件诱导ANGPTL4表达。由此作者认为缺氧肿瘤细胞可能分泌ANGPTL4与SDC1+ PCs进行通讯，从而影响其分化、存活和抗体分泌。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.2444444444444445" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CGF91SoKf9e2gmCiaEMVgwLibTUFb3mvUZ3yUiaAEsyD5FQS087KK9cDTA/640?wx_fmt=png" data-w="945" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CGF91SoKf9e2gmCiaEMVgwLibTUFb3mvUZ3yUiaAEsyD5FQS087KK9cDTA/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图5 PC与肿瘤细胞之间潜在的配体和受体相互作用</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>5. 基于L/R对的风险模型构建</strong></p></section><section powered-by="xiumi.us"><p>在这一章<span>作者进一步量化了肿瘤细胞和PCs之间的串扰模式，并评估了它们与患者生存和免疫治疗的关系。</span>基于TCGA-BLCA队列，作者从58对参与肿瘤细胞与PC之间显著通讯的L/R对中选取13个分子构建风险模型(图6A)，发现LR评分高组患者的OS明显较差(图6B)。在单因素Cox分析中，Stage、T Stage和N Stage也与OS显著相关(图6C)，而在多因素Cox分析中，剔除混杂因素后，LRscore是唯一独立的BC患者预测因子(图6C)。1年、3年、5年、7年和10年生存率的tdROC曲线下面积(AUC)表明，LRscore是比Stage、T Stage和N Stage更稳定有效的指标(图6D)。此外，在BC患者中，高LRscore也与较差的DSS、DFS和PFS相关(图6E)，这表明LRscore也有预测患者复发和进展的潜力。作者进一步评估了LRscore对抗PD-L1治疗队列患者生存的影响，高LRscore也预示着更差的OS(图6F)。同时，高风险组对治疗有反应的患者较少(图6G)，这表明LRscore可能与患者对ICB治疗的反应较差有关。LRscore与TNB和TMB 的显著负相关进一步验证了这一发现(图6H)。此外，模型分子ITGA6、HSPG2、LAMB1和SDC2的表达在应答患者中较低，这些分子的低表达与较差的OS相关(图6I和J)。这些模型分子可能是该模型成功预测抗PD-L1治疗队列免疫反应的主要原因。最后，作者评估了LRscore与其他免疫治疗相关预测因子(TNB、TMB、PD-L1、PD1和PCs)的预测效果(图6K)。LRscore联合TNB和TMB获得最高的AUC，诊断特异性为85.7%，可用于避免患者过度免疫治疗。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="0.9611111111111111" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92C9v0HnX5hEzBPYOAsJrsCa4MGsfqPzj2icnb0kH2BMprdQd0BL92M5rg/640?wx_fmt=png" data-w="1080" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92C9v0HnX5hEzBPYOAsJrsCa4MGsfqPzj2icnb0kH2BMprdQd0BL92M5rg/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图6 基于配体(L)和受体(R)的风险模型LRscore是一个很好的预后和免疫预测因子</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><p><strong>6. 评估风险模型</strong></p></section><section powered-by="xiumi.us"><p>为了更好地分析LR风险模型的特征，作者基于TCGA-BLCA队列评估了LRscore与癌症特征之间的相关性(图7A)。LRscore与大多数癌症标志呈正相关，如上皮-间质转化、血管生成、刺猬信号和缺氧。免疫细胞浸润分析显示，LRscore与大多数肿瘤抑制T细胞类型(图7B)和IPS 呈负相关(图7E)。IPS是一种免疫原性评价指标，IPS越高，免疫治疗效果越好。然而，LRscore与内皮细胞和基质细胞评分呈正相关，而与效应细胞(ECs)、免疫检查点(CPs)或整体免疫评分呈正相关(图7C和E)。更重要的是，LRscore与肿瘤免疫功能障碍及排斥(TIDE)评分之间也存在显著正相关，这种相关性主要来自于排除和CAFs，而非功能障碍(图7D)。这些数据表明，LRscore反映的免疫抑制状态可能主要是由于肿瘤基质对免疫浸润的抵抗。</p><p><br></p><p>此外，低风险组的患者大多被分类为BC的经典Robertson-LumP和共识kamoun-LumP分子亚型，而高风险组则与恶性亚型相关，如Ba/Sq、Robertson-Neuronal和kamoun-NE样亚型(图7F)。在低风险组中，肿块亚型显示出高的FGFR3突变频率(图7G)。作者还基于GDSC药物数据库对不同风险组进行了药物敏感性分析，低风险组患者对FGFR3靶向药物(如PD173074和AZD4547)的敏感性更高(图7H)。FGFR3可能成为低风险组患者的药物靶点。总的来说，这些数据表明，高LRscore预示着患者的高免疫排斥和低免疫原性，这表明较差的免疫治疗反应和OS，但低LRscore的患者可能具有更好的免疫和靶向治疗结果。</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><img data-ratio="1.1790306627101879" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CN48LzBibBz8LGznkyYvvcPMnzZHIcFMA1M8bpvdUicLIiaMUpWQZd60Lg/640?wx_fmt=png" data-w="1011" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CN48LzBibBz8LGznkyYvvcPMnzZHIcFMA1M8bpvdUicLIiaMUpWQZd60Lg/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图7 LRscore与癌症进展、微环境、癌症亚型和体细胞突变的关系</p></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section><svg xmlns="http://www.w3.org/2000/svg" viewbox="0 0 288.279 254.107" width="100%"><g><g><path d="M288.279,254.107,68.215,127.054,288.279,0ZM80.3,127.054,282.236,243.643V10.465Z" fill="rgb(62,62,62)"></path><polygon points="0 124.499 211.001 246.32 211.001 2.677 0 124.499" fill="rgb(49,102,168)"></polygon></g></g></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><p><strong>小结</strong></p></section></section></section><section><svg viewbox="0 0 1 1"></svg></section></section><section powered-by="xiumi.us"><p>在这项研究中，作者首先对来自8名患者的41894个细胞进行了scRNA-seq调查，并探索了肿瘤细胞与PCs之间的通讯模式；接下来，作者进一步通过空间转录组表达分析鉴定了关键配体/受体对，以阐明特定状态的肿瘤细胞与PCs之间的串扰；最后，作者量化了肿瘤细胞和PCs之间的总体串扰，以评估其对患者生存和对ICB治疗的反应的影响。这种多维综合分析为BC患者PCs的细胞异质性和串扰模式提供了前所未有的见解。</p><p><br></p><p>总之，作者通过整合scRNA-seq、bulk RNA-seq和空间转录组数据，系统地表征了BC中肿瘤细胞和PCs之间的串扰模式，并量化了这种串扰对患者生存和免疫治疗反应的潜在影响，基于L/R对的LRscore风险模型可用于预测临床风险和免疫反应。</p><p><br></p><p><span><strong>医学数据挖掘分析<br></strong></span></p><p><span><strong>扫码咨询</strong></span></p><p><img data-ratio="1" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CRUhbdvPeWuDBFMltgNMmZz2Jmma8ksxicDOibShIicib9Hzp3x0N3oz5Rw/640?wx_fmt=jpeg" data-type="jpeg" data-w="150" src="https://mmbiz.qpic.cn/mmbiz_jpg/N3X4LBoaQjU8wRiavC74kgtoUuNiaxV92CRUhbdvPeWuDBFMltgNMmZz2Jmma8ksxicDOibShIicib9Hzp3x0N3oz5Rw/640?wx_fmt=jpeg"></p><p><br></p></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section><section><section powered-by="xiumi.us"><p><strong>往期热点 </strong><span><strong><span>（点击标题跳转）</span></strong></span></p></section></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>01</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>线粒体质量控制</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>02</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>孟德尔随机化</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>03</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>成纤维细胞（CAFs）</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>04</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>单细胞空间转录组</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>05</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>肿瘤相关巨噬细胞（TAM）</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>06</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>细胞死亡</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>07</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>耐药</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><img data-ratio="1" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjWwWGiaDk0Xyx95BOia7rAEcD7QdhkjQbLv5jr2yh96iayNGTox4LEW0DCUVJq2FcJfB4qSJKNBQ1gnA/640?wx_fmt=png" data-w="350" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjWwWGiaDk0Xyx95BOia7rAEcD7QdhkjQbLv5jr2yh96iayNGTox4LEW0DCUVJq2FcJfB4qSJKNBQ1gnA/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><section><p>课题设计 | 组学测序 |生信分析</p><p>培训工具 | 热点互动 | 资源互换</p></section></section></section></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p><span>图文排版｜CY</span></p><p>文章转载请联系 | 15510012760（微信）</p><p>广告商务合作 | 18501253903（微信）</p></section><section powered-by="xiumi.us"><p><br></p></section></section></section><p><br></p><p><img data-galleryid="" data-ratio="1.575" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjWrzrG7FJAfjH4UKsxv3S7c2EQYQajSKA7tAAeibtZEGv8MuMGOUng5PJ0cmrCe9FSCviaib5AAYUbWA/640?wx_fmt=png" data-type="png" data-w="640" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjWrzrG7FJAfjH4UKsxv3S7c2EQYQajSKA7tAAeibtZEGv8MuMGOUng5PJ0cmrCe9FSCviaib5AAYUbWA/640?wx_fmt=png"></p><p powered-by="xiumi.us"><br></p></section><p><mp-style-type data-value="10000"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/DFbe4fLZ5jWT_FDT_IDjOQ",target="_blank" rel="noopener noreferrer">原文链接</a>
